Form 4: Omnicell Director Eileen Voynick Receives Equity Grant as Compensation

Omnicell, Inc. Director Eileen J. Voynick was granted 6,742 restricted shares of common stock as compensation for her board services, vesting on June 1, 2026.

Summary

• Eileen J. Voynick, a Director of Omnicell, Inc. (OMCL), received a grant of 6,742 restricted shares of common stock.
• The shares were granted on June 1, 2025, as compensation for her services as a Board Member under the Issuer's equity incentive plan and Board of Directors Compensation Plan.
• These shares will vest in full on the one-year anniversary of the grant date, which is June 1, 2026.
• Following this transaction, Ms. Voynick beneficially owns a total of 15,226 shares of Omnicell common stock.
• The acquisition price for these restricted shares was $0, typical for equity grants.

Sentiment

Score: 7

Explanation: The filing reports a standard equity compensation grant to a director, which is a routine corporate governance practice and aligns the director's interests with shareholders. It does not contain any unexpected positive or negative news.

Positives

• The grant of 6,742 restricted shares to Director Eileen J. Voynick aligns her interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• This equity grant is part of the company's standard Board of Directors Compensation Plan, indicating a structured and transparent approach to board remuneration.

Negatives

• No direct negative implications are apparent from this Form 4 filing, as it reports a standard equity compensation grant to a director.

Risks

• This Form 4 filing primarily reports an equity compensation grant and does not inherently introduce new risks or discuss existing company-specific risks.

Future Outlook

The 6,742 restricted shares granted to Director Eileen J. Voynick are scheduled to vest in full on June 1, 2026, which is the one-year anniversary of the grant date.

Management Comments

• No direct management comments or quotes are typically included in a Form 4 filing, which is a transactional disclosure.

Industry Context

The grant of restricted stock to a director is a common practice across industries, particularly in technology and healthcare sectors like Omnicell's, to align the interests of board members with long-term shareholder value. This type of compensation is a standard component of corporate governance and executive remuneration strategies.

Comparison to Industry Standards

• The practice of compensating board members with equity, such as restricted stock, is a widely accepted standard within corporate governance across various industries, including healthcare technology. This aligns director incentives with company performance and shareholder returns. Specific comparable companies or projects are not detailed in this Form 4 filing, as it focuses solely on the individual transaction.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The grant of restricted shares to Eileen J. Voynick, a Director of Omnicell, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, as the value of her compensation is tied to the company's stock performance.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The granted restricted shares are expected to vest in full on June 1, 2026.

Key Dates

Keywords

Omnicell, OMCL, Form 4, SEC filing, insider transaction, director compensation, restricted stock, equity grant, beneficial ownership